DJI45,990.82-0.47%
GDAXI22,362.17-1.29%
GSPC6,548.77-0.49%
HSI25,063.71+2.79%
IXIC21,782.88-0.75%
N22552,252.28+1.43%
AAPL252.16+0.27%
AMZN207.70-1.21%
CL92.45+4.90%
EURUSD1.1590-0.23%
GBPUSD1.3387-0.38%
GC4,368.60-0.88%
GOOG295.28-1.25%
JPM288.86-0.36%
META594.94-1.56%
MSFT375.04-2.13%
NVDA174.76-0.52%
TSLA385.26+1.16%
DJI45,990.82-0.47%
GDAXI22,362.17-1.29%
GSPC6,548.77-0.49%
HSI25,063.71+2.79%
IXIC21,782.88-0.75%
N22552,252.28+1.43%
AAPL252.16+0.27%
AMZN207.70-1.21%
CL92.45+4.90%
EURUSD1.1590-0.23%
GBPUSD1.3387-0.38%
GC4,368.60-0.88%
GOOG295.28-1.25%
JPM288.86-0.36%
META594.94-1.56%
MSFT375.04-2.13%
NVDA174.76-0.52%
TSLA385.26+1.16%
DJI45,990.82-0.47%
GDAXI22,362.17-1.29%
GSPC6,548.77-0.49%
HSI25,063.71+2.79%
IXIC21,782.88-0.75%
N22552,252.28+1.43%
AAPL252.16+0.27%
AMZN207.70-1.21%
CL92.45+4.90%
EURUSD1.1590-0.23%
GBPUSD1.3387-0.38%
GC4,368.60-0.88%
GOOG295.28-1.25%
JPM288.86-0.36%
META594.94-1.56%
MSFT375.04-2.13%
NVDA174.76-0.52%
TSLA385.26+1.16%
CYBERETIKAGLOBAL FINANCIAL INTELLIGENCE
LIVE
USA Seeking Alpha EN

LENZ Therapeutics GAAP EPS of -$1.16 misses by $0.26, revenue of $1.59M misses by $1.5M

Mar 24, 2026 &03112424202631; 12:11 UTC seekingalpha.com Trending 2/5
Read original on seekingalpha.com ↗
↘
Negative for markets
Sentiment score: -65/100
Moderate impact Short-term (days)
WHAT THIS MEANS
LENZ Therapeutics reported significant earnings misses (EPS -$1.16 vs -$0.90 expected, revenue $1.59M vs $3.09M expected) with a fresh 15-minute-old announcement. The stock is a micro-cap biotech with minimal revenue and substantial losses, making it highly volatile and speculative.
AI CONFIDENCE
35% Low
SENTIMENT GAUGE
NEWS POWER SCORE
AFFECTED ASSETS
⇅
LENZ
LENZStock
High volatility expected
Micro-cap biotech with massive EPS miss (-$0.26 worse than expected) and revenue miss (-$1.5M shortfall on only $1.59M total revenue = 49% miss). Fresh news but extreme volatility in small-cap biotech makes directional prediction unreliable. Market reaction unpredictable given illiquid trading and speculative nature.
PRICE HISTORY
Loading chart...
⚡ SUGGESTED ACTION
SKIP THIS TRADE. While the miss is fresh and directionally bearish, LENZ is a micro-cap biotech with extreme volatility and illiquid trading. The expected move is large (8.5%) but unpredictable—gap down is likely but not guaranteed given speculative positioning. Risk/reward is unfavorable for directional trading. [MOVE:8.5%]
KEY SIGNALS
Double earnings miss (EPS and revenue)Revenue 49% below expectationsMicro-cap biotech with minimal commercial tractionFresh catalyst but high uncertainty in executionVIX elevated at 26.63 (risk-off environment)
SECTORS INVOLVED
HealthcareBiotechnology
Analysis generated on Mar 24, 2026 at 12:26 UTC
Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

RELATED INTELLIGENCE

United Airlines bets bigger on premium travel as Iran war drives up fuel costs
BNN Bloomberg Mar 24, 17:33 Neutral
Barclays raises 2026 year-end S&P 500 target to 7,650 despite Middle East, inflation risks
BNN Bloomberg Mar 24, 17:25 Neutral
The Daily Chase: More private credit concerns
BNN Bloomberg Mar 24, 17:12 Negative
Estee Lauder in talks to merge with Jean Paul Gaultier-owner Puig in fragrance push
BNN Bloomberg Mar 24, 17:06 Positive
Private credit strains ripple through Wall Street as investors grow wary
BNN Bloomberg Mar 24, 16:52 Negative